ARTICANZ - Beta (ver 0.91)

Annotated Registry of Trials in Cancer, Australia and New Zealand Ed. - Results - target/CDK4-selective-inhibitor

Search results

target/CDK4-selective-inhibitor
9 trial(s) found.
NCT07226349
NCT06760637
NCT06756932
NCT06257264
NCT06120283
NCT05508906
NCT05216432
NCT04606446
NSW2050 - Camperdown - Chris O'Brien Lifehouse (TERMINATED)
NCT03424005
Filters
CDK4
100%
CDK4 selective
100%
oestrogen axis
100%
ER
89%
CDK6
56%
PI3Kalpha
33%
Bcl2
11%
CDK2
11%
mTOR
11%
mTORC1
11%
KAT6
11%
AKT
11%
CD40
11%
ERBB2
11%
IL-6
11%
LIV1
11%
PD-1/PD-L1
11%
PD-L1
11%
Trop2
11%
VEGF
11%




















 






























	
		
	

    

        

			ARTICANZ (Annotated Registry of Trials in Cancer, Australia/NZ Edition; ARTificial Intelligence-enhanced CANcer trial information database) provides information about cancer drug trials in Australia and New Zealand as a free, open-information platform. Please note the following:

			
    
			
  • Data Accuracy: While ARTICANZ strives to maintain accurate and up-to-date information through regular weekly updates and specialist review, we cannot guarantee the complete accuracy, reliability, or timeliness of all data. Information may change between updates.
    • 
			
			
  • Not Medical Advice: The information provided by ARTICANZ is for informational purposes only and should not be considered medical advice. All clinical decisions should be made in consultation with qualified healthcare professionals.
    • 
			
			
  • No Warranty: ARTICANZ is provided "as is" without any warranties, expressed or implied. We disclaim all liability for any damages arising from the use of or inability to use this platform.
    • 
			
			
  • External Links: ARTICANZ may contain links to external websites. We are not responsible for the content or privacy practices of these sites.
    • 
			
			


			By using ARTICANZ, you acknowledge that you have read and understood this disclaimer.
			
		

        

            
The ARTICANZ platform and its contents are made available under the Creative Commons Attribution 4.0 International License (CC BY 4.0).

            
            
Users are free to:

            
    
                
  • Share — copy and redistribute the data in any medium or format
    • 
                
  • Adapt — remix, transform, and build upon the data
    • 
                
  • Use the data for any purpose, including commercial use
    • 
            

            
            
Under the following terms:

            
    
                
  • Attribution — You must give appropriate credit to ARTICANZ, provide a link to the license, and indicate if changes were made
    • 
                
  • No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits
    • 
            

            
            
Platform developed and currently maintained by Dr. Frank Lin and the ARTICANZ team.